ASCO 2019 VIDEO: J. Leonard Lichtenfeld, MD
J. Leonard Lichtenfeld, MD, Acting Chief Medical and Scientific Officer, American Cancer...
ASCO 2019
Dr. Diefenbach and Dr. Dale
Catherine M. Diefenbach, MD, ASCO Spokesperson; NYU Langone Health William Dale, MD, PhD, ASCO...
ASCO 2019 VIDEO: Monica M. Bertagnolli, MD, Immediate Past-President, ASCO
Monica M. Bertagnolli, MD, Immediate Past-President, ASCO
ASCO 2019 Clinical Challenge: Are You an ASCO 2019 Expert?
The lights are out, the banners down, and the overflow rooms empty as the American Society of...
ASCO 2019: It Really Is All About the Targets
A quick run through the highlights and the headlines from the world’s biggest cancer meeting....
ASCO 2019: Investigational AKT Inhibitor Holds Promise in ER+ Disease
Potency is clear, but for capivasertib, toxicity is an issue CHICAGO – In a small study of...
ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1
Latest analysis from IMpassion trial confirms need for testing CHICAGO— One of the repeated themes...
ASCO 2019: Palbociclib Extends PFS in Young Women with HR+/HER2 Metastatic Breast Cancer
Korean study is first to show palbociclib benefit in premenopausal women CHICAGO—A second trial of...
ASCO 2019: NALA III Results Find ‘Modest Benefit’ for Neratinib Plus Capecitabine in Metastatic Breast Cancer
Findings hint at CNS benefit for neratinib By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO —A...
ASCO 2019: A Metavivor Offers Advice to Clinicians Treating Metastatic Breast Cancer
‘Don’t call my disease chronic.’ By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO — Kelli Davis...
ASCO 2019: SOPHIA Findings Pave Way for a New Tx Option in HER2+ Metastatic Breast Cancer
Benefit greatest in CD16A-158F carriers By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO...
ASCO 2019: CDK4/6 Inhibitors New Standard of Care for First-Line Tx
MONALEESA-7 results push the practice change needle By Peggy Peck, Editor-in-Chief, BreakingMED...
